Revolution Medicines, Inc.
RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a prā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$207.68
Price+0.17%
$0.36
1Y
Price
Market Cap
$44.152b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR-41.8%
5y CAGREarnings
-$1.768b
-56.3%
1y CAGR-60.8%
3y CAGR-64.4%
5y CAGREPS
-$8.86
-48.9%
1y CAGR-35.9%
3y CAGR-33.3%
5y CAGRBook Value
$2.606b
$4.323b
Assets$1.717b
Liabilities$641.928m
DebtDebt to Assets
14.9%
-0.4x
Debt to EBITDAFree Cash Flow
-$1.588b
-73.8%
1y CAGR-64.4%
3y CAGR-61.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company